Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M111,478Revenue $M20,765Net Margin (%)28.0Altman Z-Score2.7
Enterprise Value $M113,437EPS $7.5Operating Margin %33.8Piotroski F-Score6
P/E(ttm)19.5Beneish M-Score-2.7Pre-tax Margin (%)31.3Higher ROA y-yN
Price/Book4.110-y EBITDA Growth Rate %11.4Quick Ratio5.1Cash flow > EarningsY
Price/Sales5.55-y EBITDA Growth Rate %10.6Current Ratio5.5Lower Leverage y-yY
Price/Free Cash Flow13.5y-y EBITDA Growth Rate %14.6ROA % (ttm)8.3Higher Current Ratio y-yY
Dividend Yield %2.0PEG2.0ROE % (ttm)22.5Less Shares Outstanding y-yY
Payout Ratio %37.0Shares Outstanding M758ROIC % (ttm)20.9Gross Margin Increase y-yN

Gurus Latest Trades with AMGN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AMGNJoel Greenblatt 2015-06-30 Add0.19%$151.6 - $169.17
($160.19)
$ 147.02-8%Add 48.52%459,125
AMGNFirst Eagle Investment 2015-06-30 Reduce-0.02%$151.6 - $169.17
($160.19)
$ 147.02-8%Reduce 9.71%449,294
AMGNDodge & Cox 2015-06-30 Reduce$151.6 - $169.17
($160.19)
$ 147.02-8%Reduce 7.13%50,804
AMGNMario Gabelli 2015-06-30 Add$151.6 - $169.17
($160.19)
$ 147.02-8%Add 1.48%40,575
AMGNKen Fisher 2015-06-30 Reduce$151.6 - $169.17
($160.19)
$ 147.02-8%Reduce 0.97%155,101
AMGNJoel Greenblatt 2015-03-31 Add0.37%$150.01 - $170.1
($157.49)
$ 147.02-7%Add 2874.44%309,134
AMGNFirst Eagle Investment 2015-03-31 Reduce-0.06%$150.01 - $170.1
($157.49)
$ 147.02-7%Reduce 23.66%497,622
AMGNMario Gabelli 2015-03-31 Add$150.01 - $170.1
($157.49)
$ 147.02-7%Add 1.23%39,985
AMGNKen Fisher 2015-03-31 Add$150.01 - $170.1
($157.49)
$ 147.02-7%Add 1.41%156,623
AMGNDodge & Cox 2015-03-31 Reduce$150.01 - $170.1
($157.49)
$ 147.02-7%Reduce 17.65%54,704
AMGNVanguard Health Care Fund 2014-12-31 Reduce-0.51%$130.45 - $171.64
($155.84)
$ 147.02-6%Reduce 20.54%5,580,485
AMGNMario Gabelli 2014-12-31 Reduce-0.02%$130.45 - $171.64
($155.84)
$ 147.02-6%Reduce 34.11%39,500
AMGNJoel Greenblatt 2014-12-31 Add0.01%$130.45 - $171.64
($156.25)
$ 147.02-6%Add 285.93%10,393
AMGNVanguard Health Care Fund 2014-09-30 Reduce-0.32%$115.39 - $144.01
($130.57)
$ 147.0213%Reduce 12.75%7,022,755
AMGNFirst Eagle Investment 2014-09-30 Buy 0.25%$115.39 - $144.01
($130.57)
$ 147.0213%New holding714,178
AMGNKen Fisher 2014-09-30 Add0.02%$115.39 - $144.01
($130.57)
$ 147.0213%Add 83.59%156,629
AMGNJoel Greenblatt 2014-09-30 Reduce-0.01%$115.39 - $144.01
($130.57)
$ 147.0213%Reduce 72.90%2,693
AMGNRuane Cunniff 2014-09-30 Buy $115.39 - $144.01
($130.57)
$ 147.0213%New holding1,617
AMGNVanguard Health Care Fund 2014-06-30 Reduce-0.06%$110.29 - $126.07
($115.88)
$ 147.0227%Reduce 2.00%8,049,455
AMGNMario Gabelli 2014-06-30 Add0.02%$110.29 - $126.07
($115.72)
$ 147.0227%Add 85.28%60,335
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AMGN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


AMGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
de Carbonnel FrancoisDirector 2015-08-31Sell5,000$153.84-4.43view
Hassan FredDirector 2015-08-19Buy3,010$166.63-11.77view
PELHAM JUDITH CDirector 2015-07-31Sell5,035$180.4-18.5view
Patton Cynthia MSVP & CCO 2015-06-02Sell4,530$157.06-6.39view
Balachandran MadhavanEVP, Operations 2015-05-07Sell21,750$157.87-6.87view
Tross Stuart ASVP, Human Resources 2015-04-23Sell3,012$169.31-13.17view
Harper Sean EEVP, Research & Development 2015-04-22Sell28,000$171.58-14.31view
Tross Stuart ASVP, Human Resources 2015-03-03Sell4,415$157.74-6.8view
BALTIMORE DAVIDDirector 2015-03-02Sell3,647$158.76-7.39view
Bradway Robert AChairman, CEO and President 2015-02-11Sell22,000$152.69-3.71view

Press Releases about AMGN :

Quarterly/Annual Reports about AMGN:

News about AMGN:

Articles On GuruFocus.com
The Best Companies of the Pharmaceuticals Industry – August 2015 Aug 18 2015 
Perrigo Company Is Strong But Overvalued Jul 15 2015 
Activist Hedge Fund Manager Has Strong Focus on Health Care Stocks Jun 11 2015 
PRIMECAP Sells Portions of Its Top Two Stakes May 27 2015 
Amgen And AstraZeneca’s Deal On Psoriasis Drug Faces Termination May 27 2015 
Amgen’s Cholesterol Fighting Drug Receives EU Approval May 26 2015 
Crouching Tigers, Hidden Assets – Smead Capital Management Apr 30 2015 
securities Apr 27 2015 
Amgen Reports An Upbeat Q1 Earnings Apr 23 2015 
Amgen Inc.’s First Quarter Earnings Preview – What Could Be In Store? Apr 20 2015 

More From Other Websites
Repatha’s Clinical Profile Is Superior to Existing Statin Therapies Sep 04 2015
Amgen Biosimilar Rival Delayed After Zarxio Launch Sep 04 2015
This Stock May be Biotech's Greatest Marvel Sep 04 2015
Amgen: Time is on My Side Sep 04 2015
Amgen’s Repatha Receives FDA Approval Sep 04 2015
Novartis unit to start selling copy of Amgen drug Neupogen Sep 04 2015
Big Pharma: The Moment of Dread Is Here Sep 03 2015
Amgen (AMGN) Stock Falls as Novartis Begins Selling Biosimilar Version of Neupogen Sep 03 2015
First biosimilar hits US Sep 03 2015
Novartis to Begin Selling Copy of Amgen's Neupogen in U.S. Sep 03 2015
The Zacks Analyst Blog Highlights: Amgen, ARIAD, Celgene, Amicus and Alnylam Sep 03 2015
Novartis launches first U.S. 'biosimilar' drug at 15 pct discount Sep 03 2015
Novartis launches first U.S. 'biosimilar' drug at 15 pct discount Sep 03 2015
Novartis launches first biological copycat drug in US Sep 03 2015
First Biosimilar Drug Goes on Sale in U.S., Challenging Amgen Sep 03 2015
Amgen, Novartis Team Up; Bone Drug Positive in Phase III Sep 02 2015
Regeneron and Sanofi Present Encouraging Praluent Data Sep 02 2015
AstraZeneca Strikes Deal with Valeant for Psoriasis Drug Sep 02 2015
Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide... Sep 02 2015

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK